Imperial College London
Alternate

ProfessorWisiaWedzicha

Faculty of Medicine, National Heart & Lung Institute

Consul (clinical) for the Faculty of Medicine
 
 
 
//

Contact

 

j.wedzicha

 
 
//

Location

 

B142Guy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Wedzicha:2014:10.1016/j.rmed.2014.05.013,
author = {Wedzicha, JA and Singh, D and Vestbo, J and Paggiaro, PL and Jones, PW and Bonnet-Gonod, F and Cohuet, G and Corradi, M and Vezzoli, S and Petruzzelli, S and Agusti, A},
doi = {10.1016/j.rmed.2014.05.013},
journal = {Respiratory Medicine},
pages = {1153--1162},
title = {Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations},
url = {http://dx.doi.org/10.1016/j.rmed.2014.05.013},
volume = {108},
year = {2014}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The FORWARD study is a randomised, double-blind trial that compares the efficacy and safety of 48 weeks treatment with extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FOR), 100/6 μg pMDI, 2 inhalations BID, vs. FOR 12 μg pMDI, 1 inhalation BID, in severe COPD patients with a history of exacerbations. Co-primary endpoints were exacerbation rate over 48 weeks and pre-dose morning FEV1 at 12 weeks.The ITT population included 1186 patients (69% males, mean age 64 years) with severe airflow limitation (mean post-bronchodilator FEV1 42% predicted). Salbutamol as rescue therapy, theophylline and tiotropium (if stable regimen prior to screening) were allowed.Compared to FOR, BDP/FOR: (1) reduced the exacerbation rate (rate ratio: 0.72 [95% confidence interval 0.62–0.84], p < 0.001); (2) improved pre-dose morning FEV1 (mean difference: 0.069 L [0.043–0.095] p < 0.001); (3) prolonged the time to first exacerbation; (4) improved the SGRQ total score. The percentage of patients with adverse events was similar (52.1% with BDP/FOR and 49.2% with FOR). Pneumonia incidence was low, slightly higher with BDP/FOR (3.8%) than with FOR (1.8%). No difference for laboratory values, ECG or vital signs.Extrafine BDP/FOR significantly reduces the exacerbation rate and improves lung function of patients with severe COPD and history of exacerbations as compared to FOR alone.
AU  - Wedzicha,JA
AU  - Singh,D
AU  - Vestbo,J
AU  - Paggiaro,PL
AU  - Jones,PW
AU  - Bonnet-Gonod,F
AU  - Cohuet,G
AU  - Corradi,M
AU  - Vezzoli,S
AU  - Petruzzelli,S
AU  - Agusti,A
DO  - 10.1016/j.rmed.2014.05.013
EP  - 1162
PY  - 2014///
SN  - 1532-3064
SP  - 1153
TI  - Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations
T2  - Respiratory Medicine
UR  - http://dx.doi.org/10.1016/j.rmed.2014.05.013
UR  - http://hdl.handle.net/10044/1/40597
VL  - 108
ER  -
Download